Top-Rated StocksTop-RatedNASDAQ:PALI Palisade Bio (PALI) Stock Price, News & Analysis $0.84 -0.09 (-9.24%) Closing price 04:00 PM EasternExtended Trading$0.84 0.00 (-0.46%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Palisade Bio Stock (NASDAQ:PALI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Palisade Bio alerts:Sign Up Key Stats Today's Range$0.84▼$0.9650-Day Range$0.93▼$2.0652-Week Range$0.84▼$2.86Volume3.19 million shsAverage Volume3.57 million shsMarket Capitalization$150.58 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company Overview Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery. Palisade Bio’s candidates are in clinical development and are not approved for commercial use.AI Generated. May Contain Errors. Read More Palisade Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScorePALI MarketRank™: 3.259857612265 of 5 starsPalisade Bio scored higher than 65% of companies evaluated by MarketBeat, and ranked 510th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingBuy Consensus RatingPalisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPalisade Bio has a consensus price target of $9.00, representing about 894.5% upside from its current price of $0.91.Amount of Analyst CoveragePalisade Bio has only been the subject of 4 research reports in the past 90 days.Read more about Palisade Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Palisade Bio are expected to decrease in the coming year, from ($0.24) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palisade Bio is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palisade Bio is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalisade Bio has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted16.82% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 7.76.Change versus previous monthShort interest in Palisade Bio has recently decreased by 7.74%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPalisade Bio does not currently pay a dividend.Dividend GrowthPalisade Bio does not have a long track record of dividend growth. News and Social Media1.7 / 5News Sentiment-0.34 News SentimentPalisade Bio has a news sentiment score of -0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Palisade Bio this week, compared to 4 articles on an average week.Search InterestOnly 8 people have searched for PALI on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat Follows9 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Company Ownership3.0 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $50,500.00 in company stock, which represents 0.0311% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Palisade Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders0.07% of the stock of Palisade Bio is held by insiders.Percentage Held by Institutions11.79% of the stock of Palisade Bio is held by institutions.Read more about Palisade Bio's insider trading history. Receive PALI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PALI Stock News HeadlinesInsider Buying: Palisade Bio (NASDAQ:PALI) Director Acquires 50,000 Shares of Company StockNovember 20 at 7:37 AM | insidertrades.comFY2026 EPS Estimate for Palisade Bio Reduced by AnalystNovember 16, 2026 | americanbankingnews.comEarn $4,500 a month? Your income may count for moreEarn $4,500 or more a month? Pennie lets you explore personal loan options that consider your income, not just your credit score. Options include personal loans up to $250,000 and APRs starting at 5.99%. Checking your rate is free, and the soft credit check won't affect your score. Pennie is a loan marketplace, not a lender. Offers come from third-party partners and are not guaranteed.November 20 at 1:00 AM | Pennie Financial (Ad)FY2026 EPS Forecast for Palisade Bio Reduced by AnalystNovember 15, 2026 | americanbankingnews.comPalisade Bio (NASDAQ:PALI) Stock Gets Price Target Reduction from HC WainwrightNovember 14, 2026 | americanbankingnews.comPalisade Bio (NASDAQ:PALI) Stock Moved Down to Strong Sell by Wall Street ZenNovember 14, 2026 | americanbankingnews.comPalisade Bio Advances PALI-2108 Phase 2 Programs; Reports Q3 Results, Stock UpNovember 12, 2026 | rttnews.comPalisade Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10, 2026 | marketscreener.comMSee More Headlines PALI Stock Analysis - Frequently Asked Questions How have PALI shares performed this year? Palisade Bio's stock was trading at $2.35 at the beginning of 2026. Since then, PALI shares have decreased by 61.5% and is now trading at $0.9050. How were Palisade Bio's earnings last quarter? Palisade Bio, Inc. (NASDAQ:PALI) released its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.01. When did Palisade Bio's stock split? Shares of Palisade Bio reverse split on the morning of Monday, April 8th 2024.The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Palisade Bio's major shareholders? Palisade Bio's top institutional shareholders include Soleus Capital Management L.P. (8.36%), State Street Corp (1.68%), Goldman Sachs Group Inc. (1.52%) and HighVista Strategies LLC (0.64%). Insiders that own company stock include Robert Jr Baltera, John David Finley, Mitchell Lawrence Jones and Donald Allen Williams. View institutional ownership trends. How do I buy shares of Palisade Bio? Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Palisade Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Palisade Bio investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Plug Power (PLUG), Tilray Brands (TLRY), Tesla (TSLA), GE Aerospace (GE) and Citius Pharmaceuticals (CTXR). Company Calendar Last Earnings11/10/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PALI's financial health is in the Yellow zone, according to TradeSmith. PALI has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PALI CIK1357459 Webwww.palisadebio.com Phone(858) 704-4900FaxN/AEmployees14Year Founded2005Price Target and Rating Average Price Target for Palisade Bio$9.00 High Price Target$25.00 Low Price Target$5.00 Potential Upside/Downside+971.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.78 million Net MarginsN/A Pretax Margin-8,739.20% Return on Equity-35.60% Return on Assets-34.04% Debt Debt-to-Equity RatioN/A Current Ratio20.16 Quick Ratio20.16 Sales & Book Value Annual Sales$250 thousand Price / Sales602.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book1.33Miscellaneous Outstanding Shares179,280,000Free Float179,153,000Market Cap$150.60 million OptionableNot Optionable Beta1.61 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:PALI) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.